CDMO 3P selected to scale-up microbial production for Aussie biotech

By Dan Stanton contact

- Last updated on GMT

Helicobacter Pylori bacteria. Image: iStock/iLexx
Helicobacter Pylori bacteria. Image: iStock/iLexx

Related tags: Bacteria

Assuring anaerobic conditions in a fermenter design for aerobic organisms will be key in making Ondek’s Helicobacter pylori-based immunotherapy, says 3P Biopharmaceuticals.

Under terms of the deal – financials of which were not disclosed – the contract development and manufacturing organisation (CDMO) will make preclinical batches of an innovative immunotherapy on behalf of Ondek.

The unnamed product uses Ondek’s Helicobacter pylori​ technology which will be transferred to 3P’s facility in Navarra, Spain where scale up and non-GMP manufacture under anaerobic conditions will occur.

“We are currently performing the process at 10L in a Biostat B glass fermenter from Sartorius, and the process will be scaled-up to 100L in a SS316L Fermenter,”​ 3P spokeswoman Edurne Gil told Biopharma-Reporter.

“The key aspect of the process is assuring an anaerobic environment in a fermenter design for aerobic organisms.” ​Further details of the manufacturing process and the product itself were not disclosed.

However, 3P’s 4,500m2​ facility combines stainless steel with single use technologies “as much as posible,” ​Gil said.“We apply stainless steel technologies in those operations where the integrity of the equipment is very important due to the operational parameters described in the manufacturing procedure.”

According to Ondek, its technology harnesses the immune regulatory properties of the bacterium to develop products that are easily and safely administered for improved management of allergic and inflammatory diseases.

So far the firm has announced one product, ImmBALANCE, in development of a range of products for the management of allergic indications.

Related news

Related products

show more

Microaerobic Fermentation of Lactobacillus acidophilus

Microaerobic Fermentation of Lactobacillus acidophilus

Eppendorf for Bioprocess – Solutions that grow with you | 01-Oct-2019 | Application Note

We successfully performed microaerobic fermenta¬tion of a probiotic strain, Lactobacillus acidophilus, at a very low oxygen level, representing the natural...

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Related suppliers

Follow us

Products

View more

Webinars